These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10716492)

  • 1. Risk of sulfonylurea drugs is underappreciated.
    Lin WH; Wright JM
    J Am Coll Cardiol; 2000 Mar; 35(3):820-1. PubMed ID: 10716492
    [No Abstract]   [Full Text] [Related]  

  • 2. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.
    Garratt KN; Brady PA; Hassinger NL; Grill DE; Terzic A; Holmes DR
    J Am Coll Cardiol; 1999 Jan; 33(1):119-24. PubMed ID: 9935017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfonylurea drugs and cardiovascular mortality.
    O'Keefe JH; McCallister BD; Blackstone EH
    J Am Coll Cardiol; 1999 Sep; 34(3):958. PubMed ID: 10483986
    [No Abstract]   [Full Text] [Related]  

  • 4. Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
    Fasching P
    Diabetologia; 1998 Jun; 41(6):743-4. PubMed ID: 9662063
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral sulfonylureas and CV mortality.
    Aronow WS
    Geriatrics; 2004 Sep; 59(9):45-6, 49. PubMed ID: 15461238
    [No Abstract]   [Full Text] [Related]  

  • 6. Does mortality risk vary among sulfonylureas?
    Pantalone KM
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):6-7. PubMed ID: 25466240
    [No Abstract]   [Full Text] [Related]  

  • 7. Sulfonylureas and mortality in diabetic patients after myocardial infarction.
    Brady PA; Al-Suwaidi J; Kopecky SL; Terzic A
    Circulation; 1998 Feb; 97(7):709-10. PubMed ID: 9495313
    [No Abstract]   [Full Text] [Related]  

  • 8. Diabetes and coronary artery disease: time to stop taking the tablets.
    Edwards RJ; Rakhit RD; Marber MS
    Heart; 1999 Jun; 81(6):674. PubMed ID: 10979714
    [No Abstract]   [Full Text] [Related]  

  • 9. Sulfonylureas and the risk of myocardial infarction.
    Thisted H; Johnsen SP; Rungby J
    Metabolism; 2006 May; 55(5 Suppl 1):S16-9. PubMed ID: 16631805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Safety is the issue again].
    Overbeck P
    MMW Fortschr Med; 2013 Oct; 155(17):26. PubMed ID: 24340377
    [No Abstract]   [Full Text] [Related]  

  • 11. [Diabetes can even prolong life?].
    Füessl HS
    MMW Fortschr Med; 2014 Oct; 156(17):38. PubMed ID: 25417465
    [No Abstract]   [Full Text] [Related]  

  • 12. Summaries for patients. How do older diabetes drugs compare in their effects on heart and blood vessel disease?
    Ann Intern Med; 2012 Nov; 157(9):I-28. PubMed ID: 23128878
    [No Abstract]   [Full Text] [Related]  

  • 13. Don't throw the baby out with the bath water: mortality with combination metformin and sulfonylurea.
    Tayek JA
    Diabetes Metab Res Rev; 2007 Feb; 23(2):85-6. PubMed ID: 17262894
    [No Abstract]   [Full Text] [Related]  

  • 14. Sulfonylurea use is associated with larger infarct size in patients with diabetes and ST-elevation myocardial infarction.
    Abdelmoneim AS; Welsh RC; Eurich DT; Simpson SH
    Int J Cardiol; 2016 Jan; 202():126-30. PubMed ID: 26386939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newer Sulfonylureas Not Associated with Increased Mortality, MIs, or Strokes.
    Barry HC
    Am Fam Physician; 2016 Sep; 94(5):386. PubMed ID: 27583428
    [No Abstract]   [Full Text] [Related]  

  • 16. Glimepiride-induced vasculitis: a case report.
    Ben Salem C; Hmouda H; Bouraoui K
    Br J Clin Pharmacol; 2007 Jul; 64(1):113-4. PubMed ID: 17324240
    [No Abstract]   [Full Text] [Related]  

  • 17. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?
    Meier JJ; Gallwitz B; Schmidt WE; Mügge A; Nauck MA
    Heart; 2004 Jan; 90(1):9-12. PubMed ID: 14676228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing the diabetic patient with acute myocardial infarction.
    Fisken RA
    Diabet Med; 1998 Nov; 15(11):980. PubMed ID: 9827854
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk of a first-ever acute myocardial infarction and all-cause mortality with sulphonylurea treatment: A population-based cohort study.
    van Dalem J; Brouwers MCGJ; Stehouwer CDA; Krings A; Klungel OH; Driessen JHM; de Vries F; Burden AM
    Diabetes Obes Metab; 2018 Apr; 20(4):1056-1060. PubMed ID: 29171906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comment on 'the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy'.
    Chang Y; Choi NK; Hahn S; Park BJ
    Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1072-3; author reply 1073-4. PubMed ID: 17907252
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.